新型藥物在治療慢性副甲狀腺功能減退症方面展現出前景
New drug shows promise for chronic hypoparathyroidism treatment
Updated at: June 13, 2026 at 02:30 AM
對於患有慢性副甲狀腺機能減退症的患者而言，一項重大的醫學突破正在改變該疾病的治療方式。
For individuals living with chronic hypoparathyroidism, a significant medical breakthrough is changing how the condition is treated.
過去，患者僅依賴高劑量的口服鈣和維生素D補充劑。
Historically, patients relied solely on high-dose oral calcium and vitamin D supplements.
雖然這些補充劑有助於控制血液中的鈣濃度，但往往會導致長期問題，如腎臟損傷，且無法解決疾病的根本原因——即身體無法產生副甲狀腺素(PTH)。
While these helped manage blood calcium levels, they often caused long-term issues like kidney damage and failed to address the root cause of the disease—the body's inability to produce parathyroid hormone (PTH).
目前的醫學領域正從單純的症狀管理轉向真正的激素恢復。
The medical landscape is now shifting from simple symptom management to actual hormone restoration.
Yorvipath (palopegteriparatide) 的批准是一個重要的里程碑。
The approval of Yorvipath (palopegteriparatide) marks a major milestone.
作為同類首款長效型PTH替代療法，它以每日一次的注射方式給藥，旨在模擬人體自然的激素週期。
As the first-in-class, long-acting PTH replacement therapy, it is administered as a once-daily injection designed to mimic the body’s natural hormonal cycle.
臨床試驗顯示，它能有效維持健康的鈣濃度，改善骨骼健康，並讓許多患者減少對傳統補充劑的依賴。
Clinical trials show it effectively maintains healthy calcium levels, improves bone health, and allows many patients to reduce their reliance on traditional supplements.
除了Yorvipath，未來也充滿希望，研發管線中還有多種創新療法，包括像Canvuparatide這種每週一次的注射劑以及其他標靶受體致效劑。
Beyond Yorvipath, the future looks bright with several innovative therapies in the pipeline, including once-weekly injectables like Canvuparatide and other targeted receptor agonists.
這些進展代表了一個護理新紀元的到來，為受這種罕見內分泌疾病影響的人們提供了改善生活品質的希望。
These advancements represent a new era of care, offering hope for a better quality of life for those affected by this rare endocrine disorder.
